4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Imp

Cui, Huarui; Carlson, Angela S.; Schleiff, Mary A.; Divakaran, Anand; Johnson, Jorden A.; Buchholz, Caroline R.; Zahid, Huda; Vail, Nora R.; Shi, Ke; Aihara, Hideki; Harki, Daniel A.; Miller, Grover P.; Topczewski, Joseph J.; Pomerantz, William C.K.

doi:10.1021/acs.jmedchem.1c00933

4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Imp

Journal Article · 01 July 2021 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.1c00933· OSTI ID:1815012

Cui, Huarui; Carlson, Angela S.; Schleiff, Mary A.; Divakaran, Anand; Johnson, Jorden A.; Buchholz, Caroline R.; Zahid, Huda; Vail, Nora R.; Shi, Ke; Aihara, Hideki; Harki, Daniel A.; Miller, Grover P.; Topczewski, Joseph J.; Pomerantz, William C.K.

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; National Institutes of Health (NIH)

OSTI ID:: 1815012

Journal Information:: J. Med. Chem., Vol. 64, Issue (14)

Country of Publication:: United States

Language:: ENGLISH

References (31)

Translating the Histone Code No authors listed Science https://doi.org/10.1126/science.1063127		August 2001
Spreading Chromatin into Chemical Biology No authors listed ChemBioChem https://doi.org/10.1002/cbic.201000761		January 2011
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family No authors listed Cell https://doi.org/10.1016/j.cell.2012.02.013		March 2012
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers No authors listed Cell https://doi.org/10.1016/j.cell.2013.03.036		April 2013
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis No authors listed Molecular Cell https://doi.org/10.1016/j.molcel.2014.08.024		October 2014
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc No authors listed Cell https://doi.org/10.1016/j.cell.2011.08.017		September 2011
Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA No authors listed Molecular and Cellular Biology https://doi.org/10.1128/MCB.01365-08		December 2008
Clinical trials for BET inhibitors run ahead of the science No authors listed Drug Discovery Today: Technologies https://doi.org/10.1016/j.ddtec.2016.06.004		March 2016
The bromodomain interaction module No authors listed FEBS Letters https://doi.org/10.1016/j.febslet.2012.04.045		May 2012
Selective inhibition of BET bromodomains No authors listed Nature https://doi.org/10.1038/nature09504		September 2010
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology No authors listed Nature Chemical Biology https://doi.org/10.1038/nchembio.1471		March 2014
Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors No authors listed ACS Medicinal Chemistry Letters https://doi.org/10.1021/acsmedchemlett.9b00227		August 2019
Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A) No authors listed Bioorganic & Medicinal Chemistry Letters https://doi.org/10.1016/j.bmcl.2012.02.041		April 2012
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression No authors listed Chemistry & Biology https://doi.org/10.1016/j.chembiol.2014.05.009		July 2014
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation No authors listed Science https://doi.org/10.1126/science.aaz8455		March 2020
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer No authors listed Nature https://doi.org/10.1038/s41586-020-1930-8		January 2020
Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.0c00035		April 2020
Selective N‐Terminal BET Bromodomain Inhibitors by Targeting Non‐Conserved Residues and Structured Water Displacement** No authors listed Angewandte Chemie International Edition https://doi.org/10.1002/anie.202008625		November 2020
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling No authors listed Hepatology https://doi.org/10.1002/hep.31617		April 2021
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.0c00566		August 2020
Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/jm3010515		October 2012
Expanding the Medicinal Chemist Toolbox: Comparing Seven C(sp ² )–C(sp ³ ) Cross-Coupling Methods by Library Synthesis No authors listed ACS Medicinal Chemistry Letters https://doi.org/10.1021/acsmedchemlett.0c00093		March 2020
Expanding the medicinal chemistry synthetic toolbox No authors listed Nature Reviews Drug Discovery https://doi.org/10.1038/nrd.2018.116		August 2018
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?: Miniperspective No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.5b01409		December 2015
Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.0c00021		April 2020
The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.6b00472		June 2016
Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase–Bromodomain Inhibitor No authors listed Journal of Medicinal Chemistry https://doi.org/10.1021/acs.jmedchem.8b01248		September 2018
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings No authors listed Advanced Drug Delivery Reviews https://doi.org/10.1016/j.addr.2012.09.019		December 2012
Phaser crystallographic software No authors listed Journal of Applied Crystallography https://doi.org/10.1107/S0021889807021206		July 2007
PHENIX: a comprehensive Python-based system for macromolecular structure solution No authors listed Acta Crystallographica Section D Biological Crystallography https://doi.org/10.1107/S0907444909052925		January 2010
Features and development of Coot No authors listed Acta Crystallographica Section D Biological Crystallography https://doi.org/10.1107/S0907444910007493		March 2010

Similar Records

4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Imp

Journal Article · 2021 · J. Med. Chem. · OSTI ID:1818348

Cui, Huarui; Carlson, Angela S.; Schleiff, Mary A.; +11 more

Discovery of N -(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1 H -pyrrolo[2,3- c ]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Journal Article · 2017 · Journal of Medicinal Chemistry · OSTI ID:1414456

McDaniel, Keith F.; Wang, Le; Soltwedel, Todd; +29 more

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1734924

Sheppard, George S.; Wang, Le; Fidanze, Steven D.; +20 more

4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Imp

Citation Formats

References (31)

Similar Records

Related Subjects